Biotech stocks have fallen to earth with a thud in 2021 after soaring last year amid excitement over the development of Covid-19 vaccines, dealing big losses to some hedge funds.
The sector is being buffeted by concerns Congress will move to put a lid on drug pricing and a surfeit of early-stage biotech shares as the IPO market booms.
Studying Time: 3 minutes Kailyn Lowry has moved on. Once more. About two months in the past, Lowry broke up…
CLOVIS —After Clara Adams appeared to have develop into a state monitor…
In a serious improvement affecting one of the crucial contentious land use…
The U.S. has struggled with a employee scarcity in semiconductor…
